Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    80
    ...
ATC Name B/G Ingredients Dosage Form Price
A03BA01 ATROPINE SULFATEAGUETTANT G Atropine - 0.1mg/ml 0.1mg/ml Injectable solution 7,805,376 L.L
A10BA02 MINOR G Metformin HCl - 1g 1g Tablet 266,209 L.L
A12AX OSTRONG G Vitamin D3 - 500IU, Calcium hydrogen phosphate - 600mg Tablet 435,149 L.L
B05XA03 ISOTONIC SALINE G Sodium chloride - 0.9% 0.9% Injectable solution 174,553 L.L
C07AB02 B-BLOK SDK G Metoprolol succinate - 50mg 50mg Tablet, controlled release 295,645 L.L
C09DA01 LOSARTAN/HYDROCHLOROTHIAZIDE ARROW LAB G Losartan potassium - 100mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 470,345 L.L
J01MA12 ILFLOX G Levofloxacin - 500mg 500mg Tablet, film coated 587,259 L.L
L01EF01 PAPILLIO G Palbociclib - 100mg 100mg Capsule, hard 147,883,080 L.L
M01AC01 INFLACAM G Piroxicam - 20mg/ml 20mg/ml Injectable solution 193,513 L.L
N01BB09 ROPIVACAINA MOLTENI G Ropivacaine HCl - 75mg/10ml 7.5mg/ml Injectable solution 2,332,911 L.L
N03AX11 TOPIRAMATE ARROW G Topiramate - 50mg 50mg Tablet, film coated 765,990 L.L
N05BA12 ALPRAZOLAM BIOGARAN G Alprazolam - 0.5mg 0.5mg Tablet, scored 169,324 L.L
P01AB01 METRONIDAZOLE BIOGARAN G Metronidazole - 250mg 250mg Tablet, coated 143,791 L.L
R05X COFEX G Paracetamol - 33.3mg/5ml, Guaifenesin - 33.3mg/5ml, Oxomemazine HCl - 1.65mg/5ml Syrup 154,542 L.L
V03AB35 RELANCIUM G Sugammadex - 100mg/ml 100mg/ml Injectable solution 45,660,028 L.L
B05XA03 ISOTONIC SALINE G Sodium chloride - 0.9% 0.9% Injectable solution 167,780 L.L
C09DA01 LOSARTAN/HYDROCHLOROTHIAZIDE BGR G Losartan potassium - 100mg, Hydrochlorothiazide - 25mg Tablet, coated 439,436 L.L
D11AH01 TACRUS G Tacrolimus monohydrate - 0.1% 0.1% Ointment 1,857,190 L.L
G04CA04 SILODOSINE ARROW G Silodosine - 4mg 4mg Capsule 732,394 L.L
J01MA12 JOSWE AVOXIN 500 G Levofloxacin - 500mg 500mg Tablet, film coated 786,148 L.L
J07BD52 MEASLES, MUMPS AND RUBELLA VACCINE LIVE ATTENUATED (FREEZE-DRIED) MMR G Rubella virus live attenuated - ?1000CCID50 /0.5ml, Mumps virus live attenuated - ?5000CCID50 /0.5ml, Measles virus live attenuated - ?1000CCID50 /0.5ml Injectable freeze dried powder + diluent 739,113 L.L
M01AC01 INFLACAM G Piroxicam - 20mg/ml 20mg/ml Injectable solution 190,826 L.L
N01BB09 ROPIVACAINE B. BRAUN G Ropivacaine HCl - 75mg/10ml 7.5mg/ml Injectable solution 4,831,114 L.L
N03AX11 TOPIRATE 50 BENTA G Topiramate - 50mg 50mg Tablet, film coated 1,407,835 L.L
N05BA12 ALPROX G Alprazolam - 0.5mg 0.5mg Tablet 383,955 L.L
P01AB07 SNAD G Secnidazole - 500mg 500mg Tablet 774,053 L.L
V03AB35 ? SUGAMMADEX G Sugammadex - 200mg/2ml 100mg/ml Injectable solution 5,214,109 L.L
L01CE02 IRINOTECAN THYMOORGAN G Irinotecan HCl - 40mg/2ml 40mg/2ml Injectable concentrated solution L.L
A10BA02 DIANORM XR 750 G Metformin HCl - 750mg 750mg Tablet, film coated, extended release 500,421 L.L
B05XA03 ISOTONIC SALINE G Sodium chloride - 0.9% 0.9% Injectable solution 170,630 L.L
    ...
    80
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026